Ladostigil (TV-3326) is an orally active dual inhibitor ofcholinesteraseand brain-selectivemonoamine oxidase(MAO), withIC₅₀s of 37.1 and 31.8 μM forMAO-BandAChE, respectively. Ladostigil exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease^[1][2].

Ladostigil (1-10 μM) exerts neuroprotective activities, including a prevention of the fall of the mitochondrial membrane potential (ψ), attenuation of apoptotic cascades and an inhibition of ROS production induced by OS insults^[2].
Ladostigil (1-10 μM) has a significant neuroprotective activity, including inhibition of caspase-3 activation, induction of Bcl-2 and reduction of Bad and Bax gene and protein expression in human neuroblastoma SK-N-SH cells^[2].

Ladostigil (17 mg/kg; p.o. daily for 6 weeks) abolishes their hyperanxiety and depressive-like behaviour in the elevated plus maze (EPM) and forced swim tests (FST) tests in adulthood from puberty to prenatally-stressed rats^[4].
Ladostigil (50 μmol/kg; single p.o.) restores the loss of episodic memory in the object recognition test in rats^[3].

272.34

C₁₆H₂₀N₂O₂

209394-27-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.